Norges Bank Kiniksa Pharmaceuticals, Ltd. Transaction History

Norges Bank

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 10, 2021	SELL	$13.22 - $19.09 $290,139 - $418,968	-21,947 Closed	0 $0
Q1 2021 May 09, 2022	BUY	$16.68 - $23.97 $366,075 - $526,069	21,947 New	21,947 $406,000
Q1 2021 May 07, 2021	SELL	$16.68 - $23.97 $1.13 Million - $1.62 Million	-67,596 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$14.8 - $21.15 $1 Million - $1.43 Million	67,596 New	67,596 $1.19 Million
Q4 2020 Feb 10, 2021	SELL	$14.8 - $21.15 $1.82 Million - $2.61 Million	-123,221 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$15.21 - $25.53 $1.87 Million - $3.15 Million	123,221 New	123,221 $1.89 Million
Q3 2020 Nov 10, 2020	SELL	$15.21 - $25.53 $620,963 - $1.04 Million	-40,826 Closed	0 $0
Q2 2020 Aug 13, 2021	BUY	$15.08 - $26.0 $615,656 - $1.06 Million	40,826 New	40,826 $1.04 Million
Q2 2020 Aug 07, 2020	SELL	$15.08 - $26.0 $272,586 - $469,976	-18,076 Closed	0 $0
Q1 2020 May 07, 2021	BUY	$11.0 - $19.76 $198,836 - $357,181	18,076 New	18,076 $280,000

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $680M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.